北京市金杜（青岛）律师事务所 关于海利尔药业集团股份有限公司 致：海利尔药业集团股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受海利尔药业集团股份 有限公司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称 《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券 监督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人 民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章和规范性文件以及现行有效的《海利尔药业集团股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于2025年5月22日召开的 出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 《公司章程》； 下同）及上海证券交易所网站（http://www.sse.com.cn/，下同）的《海利尔药业 集团股份有限公司关于第五届董事会第八次会议决议的公告》； 利尔药业集团股份有限公司关于第五届监事会第八次会议决议的公告》； 利尔药业集团股份有限公司关 ...

证券代码：603639 证券简称：海利尔 公告编号：2025-032 海利尔药业集团股份有限公司 关于子公司制剂项目通过环保验收的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、项目投资概述 海利尔药业集团股份有限公司（以下简称"公司"）于 2019 年 10 月 28 日召 开第三届董事会第三十三次会议，审议通过了《关于青岛奥迪斯生物科技有限公 司拟投资新建制剂项目的议案》，同意青岛奥迪斯生物科技有限公司新建制剂项 目，各制剂项目按需逐步进行投资建设，建设周期预期到 2021 年，资金预算为 27,615.00 万元。具体内容详见公司于 2019 年 10 月 29 日刊登在指定信息披露 媒体《中国证券报》、《上海证券报》和上海证券交易所网站（www.sse.com.cn） 上的《海利尔关于青岛奥迪斯生物科技有限公司拟投资新建制剂项目的公告》（公 告编号：2019-077）。 2020 年 8 月 27 日，公司第四届董事会第一次会议审议通过《关于青岛奥迪 斯生物科技有限公司变更投资新建项目的议案》，同意青岛奥迪斯 ...

北京市金杜（青岛）律师事务所 关于海利尔药业集团股份有限公司 2024 年年度股东大会之法律意见书 致：海利尔药业集团股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受海利尔药业集团股份 有限公司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称 《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券 监督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人 民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章和规范性文件以及现行有效的《海利尔药业集团股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于2025年5月22日召开的 2024年年度股东大会（以下简称本次股东大会），并就本次股东大会的相关事项 出具本法律意见书。 4. 公司 2025 年 4 月 29 日披露于巨潮资讯网及上海证券交易所网站的《海 1 利尔药业集团股份有限公司关于召开 2024 年年度股东大会的通知》（以下简称 《股东大会通知》）； 5. 公司本次股东大会股权登 ...

证券代码：603639 证券简称：海利尔 公告编号：2025-031 海利尔药业集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 22 日 (二)股东大会召开的地点：青岛市城阳区国城路 216 号公司五楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 92 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 226,067,685 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 66.5103 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长葛家成先生主持。会议的出席人员、人数及召集、召开和表决 方式符合《中华人民共和国公司法》《上海证券交易所股票上市规则》《海利尔 审议 ...

海利尔药业集团股份有限公司 海利尔药业集团股份有限公司 2024 年年度股东大会会议议程 2024 年年度股东大会 一、会议召开的基本情况 会议材料 二、会议议程 二〇二五年五月二十二日 （一）会议类型和届次：2024 年年度股东大会 （二）会议召开时间、地点： 会议时间：2025 年 5 月 22 日 14:30-16:00 会议地点：青岛市城阳区国城路 216 号五楼会议室 （三）会议出席人员 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）全体与会股东或股东代表、列席会议的董事、监事、高级管理人员签到； （二）报告会议出席情况，宣布会议开始； （三）本次股东大会各项议案宣读并审议； （四）股东或股东代表发言及公司董事、监事、高级管理人员回答提问； （五）记名投票表决（由股东、监事及律师组成的表决统计小组进行统计）； （六）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结果； （七）网络投票结果产生后，宣读投票结果和决议； （八）律师宣读本次股东大会法律意见书，董事在股东大会决议及会议记录上签字； （九）宣布会议结束。 海利尔药业集团股份有限公司 ...

海利尔药业集团股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日暨 2024 年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603639 证券简称：海利尔 公告编号：2025-030 为进一步加强与投资者的互动交流，海利尔药业集团股份有限公司（以下简 称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络 有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日暨 2024 年度业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司董事长葛家成先生，财务负责人刘玉龙先生，董事会秘书迟明明女士， 独立董事杨爱义先生将以在线交流形式就公司治理、发展战略、经营状况、融资 计划、股权激励和可持续 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5][7]. Core Insights - The company reported a decline in net profit for 2024 but showed improvement in Q1 2025, with a net profit of 1.05 billion yuan, a year-on-year increase of 15.64% and a quarter-on-quarter increase of 82.22% [1][2]. - The decrease in revenue for 2024 was primarily due to falling prices of certain pesticide products, which could not be offset by increased sales volume [2]. - The company is actively expanding its overseas market presence, having obtained over 2,100 product registrations in various countries [4]. Summary by Sections Financial Performance - In 2024, the company achieved revenue of 3.908 billion yuan, a year-on-year decrease of 11.16%, and a net profit of 181 million yuan, down 61.67% [1][6]. - For Q1 2025, revenue was 1.264 billion yuan, up 10.16% year-on-year and up 82.22% quarter-on-quarter, with a net profit of 105 million yuan [1][2]. Product and Market Strategy - The company is focusing on a strategy that integrates formulation, active ingredients, and intermediates, which helps mitigate the cyclical risks associated with active ingredient production [3]. - The company has a diverse product portfolio with 254 pesticide registration certificates, covering various categories such as insecticides, fungicides, and herbicides [4]. Profitability and Valuation - The report projects a decline in net profit for 2025 to 396 million yuan, down 28.6% from previous estimates, with further projections for 2026 and 2027 showing gradual recovery [5][6]. - The company's earnings per share (EPS) is expected to be 1.16 yuan in 2025, with a price-to-earnings (P/E) ratio of 11 [6][14].

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company reported better-than-expected performance driven by the peak season for formulations in Q1 2025, while continuing to advance the construction of the Hengning base to strengthen its integrated strategy of intermediates, active ingredients, and formulations [1][6] Financial Performance Summary - In 2024, the company achieved total revenue of 39.08 billion yuan, a year-on-year decrease of 11.2%, and a net profit attributable to the parent company of 1.81 billion yuan, down 61.7% year-on-year [5][6] - For Q1 2025, the company reported revenue of 12.64 billion yuan, a year-on-year increase of 10.2%, and a net profit of 1.05 billion yuan, up 16% year-on-year [6] - The company plans to distribute a cash dividend of 5 yuan per 10 shares, representing 93.7% of the net profit attributable to the parent company [6] Revenue and Profit Forecast - Projected total revenue for 2025 is 44.52 billion yuan, with a year-on-year growth rate of 13.9% [5] - The forecasted net profit for 2025 is 3.65 billion yuan, reflecting a significant increase of 101.3% compared to 2024 [5][6] - The company expects to gradually reduce losses from the Hengning base in 2025, with new investments supporting future growth [6] Market and Product Insights - The company's pesticide business saw a sales volume of 56,600 tons in 2024, with a revenue of 38.08 billion yuan, despite a year-on-year price decline of 14% [6] - In Q1 2025, the pesticide business achieved a sales volume of 17,200 tons, with revenue of 12.31 billion yuan, indicating a recovery in demand [6] - The report highlights that the formulation business is expected to contribute nearly half of the company's revenue during the peak sales season in H1 2025 [6]

Group 1 - The core viewpoint of the article highlights the strategic breakthroughs and innovations of Shandong Keda Group in the oilfield market, particularly in Southeast Asia, through the development of new high-temperature and salt-resistant polymers and modified polyacrylamide products [1] - Shandong Keda Group has maintained its competitive edge in traditional oilfield markets while successfully expanding into new markets, laying a solid foundation for its Asia-Pacific and global layout [1] - The company emphasizes the importance of continuous R&D innovation and optimizing product structure to create a series of high-quality products with core competitiveness [1] Group 2 - Shandong Keda Group has been recognized as a top 500 Chinese enterprise for 18 consecutive years and is the only private enterprise in Shandong with a special-grade qualification for highway engineering construction [3] - The company has leveraged its multi-sector collaboration advantages in various projects, such as highways and bridges, to shorten project preparation cycles and improve profit margins [3] - Keda Group has implemented a comprehensive incentive mechanism for talent development in emerging business areas, focusing on performance rewards, growth empowerment, and shared benefits [3] Group 3 - Zhongfu Information Co., Ltd. is noted as one of the earliest private enterprises in China engaged in the research and development of confidentiality and security products, and it was the first in the sector to be listed on the A-share market [3] - The company has established a nationwide market and technical service network, focusing on confidentiality and data security, and aims to enhance its product competitiveness in response to evolving user demands [4][5] - Hailier Pharmaceutical Group, founded in 1999, specializes in agricultural pest control and has become a global leader in the supply of various pesticide products, with operations in over 100 countries [5] Group 4 - Hailier Pharmaceutical Group invests over 4.5% of its annual revenue in R&D, focusing on green raw materials and environmentally friendly formulations, and has developed new pesticides that increase crop yields by 30% [5] - The company is also engaged in the development of nano-pesticides and biological pesticides that meet drone application standards [5] Group 5 - Recent policies in Shandong, such as the "38 measures for the private economy" and "comprehensive economic stabilization policies," aim to promote economic development by simplifying approval processes and optimizing the business environment for private enterprises [6]

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].